~~<i id='6F1013C6A5'><strike id='6F1013C6A5'><tt id='6F1013C6A5'><pre id='6F1013C6A5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：knowledge 2025-09-06 02:03:17 - browse：698

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Why Novartis is changing the name of its research labs

focus

leisure time

knowledge

hotspot

explore

Asantibioticsresearchshrivels,thebraindrainawayfromthisfieldwillhavemanylabslookingthisempty.AdobeIn

WSS

Intellia reports positive results for its CRISPR

Change Healthcare can notify patients about the breach, HHS says

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Cord blood banking comes at a high cost to babies

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

ASCO: AstraZeneca says CAR

Wikipedia

entertainment

focus

At least 13 dead in Texas as scorching temps continue

Amazon on where the company's health care bets are headed next

At least 13 dead in Texas as scorching temps continue

Humana sues Biden admin over Medicare Advantage audit rule

How one medical school became remarkably diverse

At ASCO, AstraZeneca reports strong data for breast cancer drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humana sues Biden admin over Medicare Advantage audit rule

Affirmative action in medical school literally saved lives

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

See how much Covid

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

AstraZeneca chief proposes a novel edit to the drug pricing bill

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Humana sues Biden admin over Medicare Advantage audit rule

leisure time

knowledge

hotspot

explore